Ignite Creation Date:
2024-05-05 @ 11:19 PM
Last Modification Date:
2024-10-26 @ 10:32 AM
Study NCT ID:
NCT01305239
Status:
TERMINATED
Last Update Posted:
2012-04-10
First Post:
2011-02-24
Brief Title:
A Survey Of Clinical Practice Of Adjuvant Treatment Of Breast Cancer Using Exemestane Aromasin In Postmenopausal Hr Patients
Sponsor:
Pfizer
Organization:
Pfizer
Study Overview
Official Title:
A Survey Of Clinical Practice Of Adjuvant Treatment Of Breast Cancer Using Exemestane Aromasin In Postmenopausal Hr Patients
Status:
TERMINATED
Status Verified Date:
2011-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
See termination reason in detailed description
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ETAPE
Brief Summary:
Observational survey aiming to evaluate the tolerability of Aromasin and the ways in which it is used in clinical practice in France as adjuvant endocrine therapy
Detailed Description:
It was hypothesized that 200 participating doctors would provide the survey with sufficient statistical precision to meet the objectives with each participating doctor recruiting up to 6 patients An initial sample of 1000 doctors should be contacted letter phone
These 1000 doctors will initially be chosen at random from a file held by Pfizer of doctors who have agreed to take part in a Pfizer survey
These doctors will be experienced and qualified in the treatment and management of patients with non-metastatic surgically-treated breast cancer medical oncologists gynaecologists and medical oncologists radiation oncologists They are practicing in general hospitals teaching hospitals CRLCC cancer centres and private clinics treating patients with breast cancer
Study recruitment was stopped due to difficulty in enrolling the targeted number of patients on December 3 2010 There were no safety concerns involved in the decision to stop enrollment
These 1000 doctors will initially be chosen at random from a file held by Pfizer of doctors who have agreed to take part in a Pfizer survey
These doctors will be experienced and qualified in the treatment and management of patients with non-metastatic surgically-treated breast cancer medical oncologists gynaecologists and medical oncologists radiation oncologists They are practicing in general hospitals teaching hospitals CRLCC cancer centres and private clinics treating patients with breast cancer
Study recruitment was stopped due to difficulty in enrolling the targeted number of patients on December 3 2010 There were no safety concerns involved in the decision to stop enrollment
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| A5991095 ETAPE | None | None | None |